Tratamiento antitrombótico doble frente a triple

Neumann, 2019, 2018 ESC/EACTS Guidelines on myocardial revascularization, Eur Heart J, 40, 87, 10.1093/eurheartj/ehy394 Lip, 2018, Europace Kirchhof, 2016, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur HeartJ, 37, 2893, 10.1093/eurheartj/ehw210 Rubboli, 2015, New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint, Int J Cardiol, 196, 133, 10.1016/j.ijcard.2015.06.006 Angiolillo, 2016, Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective—2016 Update, Circ Cardiovasc Interv, 9, e004395, 10.1161/CIRCINTERVENTIONS.116.004395 Steffel, 2018, The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur Heart J, 39, 1330, 10.1093/eurheartj/ehy136 Valgimigli, 2018, Eur Heart J, 39, 213, 10.1093/eurheartj/ehx419 Levine, 2016, 2016 ACC/AHA Guideline Focused Update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 68, 1082, 10.1016/j.jacc.2016.03.513 Capodanno, 2018, Triple antithrombotic therapy after ACS and PCI in patients on chronic oral anticoagulation: update, Heart, 10.1136/heartjnl-2017-312228 Duerschmied, 2018, Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and REDUAL PCI trials?, Clin Res Cardiol, 107, 533, 10.1007/s00392-018-1242-2 Kerneis, 2018, Triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention, Prog Cardiovasc Dis, 60, 524, 10.1016/j.pcad.2018.01.008 Sørensen, 2009, Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data, Lancet, 374, 1967, 10.1016/S0140-6736(09)61751-7 Cavallari, 2018, Meta-analysis comparing the safety and efficacy of dual versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, Am J Cardiol, 121, 718, 10.1016/j.amjcard.2017.12.014 Golwala, 2018, Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials, Eur Heart J, 39, 1726, 10.1093/eurheartj/ehy162 Lamberts, 2012, Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study, Circulation, 126, 1185, 10.1161/CIRCULATIONAHA.112.114967 Schömig, 1996, A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents, N Engl J Med, 334, 1084, 10.1056/NEJM199604253341702 Leon, 1998, A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators, N Engl J Med, 339, 1665, 10.1056/NEJM199812033392303 Urban, 1998, Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS), Circulation, 98, 2126, 10.1161/01.CIR.98.20.2126 Bertrand, 1998, Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full ANTicoagulation versus ASpirin and TIClopidine (FANTASTIC) study, Circulation, 98, 1597, 10.1161/01.CIR.98.16.1597 Brener, 2016, The impact of timing of ischemic and hemorrhagic events on mortality after percutaneous coronary intervention: The ADAPT-DES Study, JACC Cardiovasc Interv, 9, 1450, 10.1016/j.jcin.2016.04.037 Secemsky, 2015, Comparison of short-and long-term cardiac mortality in early versus late stent thrombosis (from pooled PROTECT trials), Am J Cardiol, 115, 1678, 10.1016/j.amjcard.2015.03.010 Connolly, 2006, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet, 36726, 1903 Wustrow, 2018, Real clinical experiences of dual versus triple antithrombotic therapy after percutaneous coronary intervention, Catheter Cardiovasc Interv, 10.1002/ccd.27678 Kawai, 2015, Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting, J Cardiol, 65, 197, 10.1016/j.jjcc.2014.08.013 Dewilde, 2013, Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial, Lancet, 381, 1107, 10.1016/S0140-6736(12)62177-1 Capodanno, 2015, Triple therapy for atrial fibrillation and ACS with or without PCI: don’t drop aspirin just yet, J Am Coll Cardiol, 65, 515, 10.1016/j.jacc.2014.10.063 Fiedler, 2015, Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE Trial, J Am Coll Cardiol, 65, 1619, 10.1016/j.jacc.2015.02.050 Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 Gibson, 2016, Prevention of bleeding in patients with atrial fibrillation undergoing PCI, N Engl J Med, 375, 2423, 10.1056/NEJMoa1611594 Cannon, 2017, Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation, N Engl J Med, 377, 1513, 10.1056/NEJMoa1708454 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Lopes, 2019, Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation, N Engl J Med, 10.1056/NEJMoa1817083 Angiolillo, 2010, Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions, Rev Esp Cardiol, 63, 60, 10.1016/S0300-8932(10)70010-5 Lugo, 2018, Dual antiplatelet therapy after coronary stent implantation: Individualizing the optimal duration, J Cardiol, 72, 94, 10.1016/j.jjcc.2018.03.001 Sarafoff, 2013, Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation, J Am Coll Cardiol, 61, 2060, 10.1016/j.jacc.2013.02.036 Verlinden, 2017, Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticagrelor versus clopidogrel, J Cardiovasc Pharmacol Ther, 22, 546, 10.1177/1074248417698042 Yao, 2017, Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction, J Am Coll Cardiol, 69, 2779, 10.1016/j.jacc.2017.03.600